Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).
Fiche publication
Date publication
février 2018
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAUCHESNE Patrick, Pr GHIRINGHELLI François, Pr TAILLANDIER Luc
Tous les auteurs :
Reyes-Botero G, Cartalat-Carel S, Chinot OL, Barrie M, Taillandier L, Beauchesne P, Catry-Thomas I, Barrière J, Guillamo JS, Fabbro M, Frappaz D, Benouaich-Amiel A, Le Rhun E, Campello C, Tennevet I, Ghiringhelli F, Tanguy ML, Mokhtari K, Honnorat J, Delattre JY
Lien Pubmed
Résumé
Results suggest that the combination of bevacizumab plus temozolomide is active in terms of response rate, survival, performance, quality of life, and cognition in elderly patients with glioblastoma multiforme with poor performance status.Whether this combination is superior to temozolomide alone remains to be demonstrated by a randomized study.
Référence
Oncologist. 2018 Feb 22;: